Twitter

Posts Tagged ‘inhibitor’


Commonly used drug can limit radiation damage to lungs and heart for cancer patients

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumors in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

Read More...

FDA Step Closer To Approving Breast Cancer Drug "Palbociclib"

The pharmaceutical giant Pfizer has just announced that their drug “Palbociclib”, a selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has just received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for breast cancer treatment. Breast cancer is the most common cancer among women worldwide…

Read More...

Promising Phase I Clinical Trial Of Rogosertib Leads To Multi-Institutional Phase II Trial

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors…

Read More...

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO -dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer .

Read More...

Study finds potential to match tumors with known cancer drugs

Researchers have found a new way to match potential cancer treatments with an individual tumor: assess the landscape of kinases and find a kinase inhibitor that goes after the highest-expressing kinases in that tumor.

Read More...

Treatment targeting PI3K may delay resistance to anti-HER2 therapy in breast cancer patients

Patients with HER2-positive breast cancer being treated with anti-HER2 therapy may be able to prevent or delay resistance to the therapy with the addition of a phosphatidylinositol-3 kinase inhibitor to their treatment regimens.

Read More...

Dr. Richard Furman on Trials Examining Ibrutinib’s Safety in ChronicLymphocytic Leukemia

Richard R. Furman, MD, director of the Chronic Lymphocytic Leukemia (CLL) Research Center and a senior member of the Center for Lymphoma and Myeloma at the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia (CLL). For more information on ibrutinib in CLL, read www.onclive.com

Read More...

Researchers investigate dasatinib in combination with other drugs for advanced, recurrent ovarian cancer

Researchers have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.

Read More...

Combination treatment may improve survival of breast cancer patients with brain metastases

Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. Investigators report the first preclinical study combining antiangiogenic and anti-HER2 drugs in an animal model of brain metastatic breast cancer.

Read More...

In Mice, Combining Cancer Vaccine and Low-Dose Anti-Angiogenesis Drug Shows Promise against Breast Cancer

A combination of a therapeutic cancer vaccine and low doses of a drug that blocks tumor blood vessel growth (an angiogenesis inhibitor) may be an effective treatment for breast cancer, according to a study in mice.

Read More...